Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials
This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two comp...
Saved in:
Published in | Cancers Vol. 12; no. 11; p. 3251 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
MDPI AG
04.11.2020
MDPI |
Subjects | |
Online Access | Get full text |
ISSN | 2072-6694 2072-6694 |
DOI | 10.3390/cancers12113251 |
Cover
Abstract | This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials’ primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles. |
---|---|
AbstractList | This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials' primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles.This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials' primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles. In cancer clinical trials, adverse event data are collected after every treatment cycle, using the Common Terminology Criteria for adverse events, which includes 837 terms. The vast number of potentially reportable adverse events over multiple treatment cycles makes summarizing and analyzing adverse event data challenging. The current standard reporting of adverse event data includes the frequency of the maximum (worst) grade of commonly occurring adverse events. In this article, we propose a single quantitative summary measure that incorporates both the frequency and the severity of multiple adverse events over time; the adverse event burden score. This score is a well-defined measure that enables statistical comparisons analogous to other quantitative endpoints in clinical trials. The adverse event burden score can readily accommodate different trial settings, diseases, and treatments, with diverse safety profiles. This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced across all treatment cycles. AE data from two completed Alliance multi-center randomized double-blind placebo-controlled trials, with different AE profiles (NCCTG 97-24-51: 176 patients, and A091105: 83 patients), were utilized for illustration. Results of the AE burden score analyses corroborated the trials’ primary results. In 97-24-51, the overall AE burden for patients on the treatment arm was 2.2 points higher than those on the placebo arm, with a higher AE burden for patients who went off treatment early due to AE. Similarly, in A091105, the overall AE burden was 1.6 points higher on the treatment arm. On the placebo arms, the AE burden in 97-24-51 remained constant over time; and increased in later cycles in A091105, likely attributable to the increase in disease morbidity. The AE burden score enables statistical comparisons analogous to other quantitative endpoints in clinical trials, and can readily accommodate different trial settings, diseases, and treatments, with diverse AE profiles. |
Audience | Academic |
Author | Jatoi, Aminah Storrick, Elizabeth Le-Rademacher, Jennifer G. Thall, Peter F. Mandrekar, Sumithra J. Hillman, Shauna Mahoney, Michelle R. |
AuthorAffiliation | 2 IQVIA, Raleigh-Durham, NC 27703, USA; mahoney.michelle@mayo.edu 1 Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; hillman.shauna@mayo.edu (S.H.); storrick.elizabeth@mayo.edu (E.S.); mandrekar.sumithra@mayo.edu (S.J.M.) 4 Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA; jatoi.aminah@mayo.edu 3 Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX 77230, USA; rex@mdanderson.org |
AuthorAffiliation_xml | – name: 4 Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA; jatoi.aminah@mayo.edu – name: 1 Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA; hillman.shauna@mayo.edu (S.H.); storrick.elizabeth@mayo.edu (E.S.); mandrekar.sumithra@mayo.edu (S.J.M.) – name: 3 Department of Biostatistics, M.D. Anderson Cancer Center, Houston, TX 77230, USA; rex@mdanderson.org – name: 2 IQVIA, Raleigh-Durham, NC 27703, USA; mahoney.michelle@mayo.edu |
Author_xml | – sequence: 1 givenname: Jennifer G. orcidid: 0000-0002-2234-7430 surname: Le-Rademacher fullname: Le-Rademacher, Jennifer G. – sequence: 2 givenname: Shauna surname: Hillman fullname: Hillman, Shauna – sequence: 3 givenname: Elizabeth surname: Storrick fullname: Storrick, Elizabeth – sequence: 4 givenname: Michelle R. surname: Mahoney fullname: Mahoney, Michelle R. – sequence: 5 givenname: Peter F. surname: Thall fullname: Thall, Peter F. – sequence: 6 givenname: Aminah surname: Jatoi fullname: Jatoi, Aminah – sequence: 7 givenname: Sumithra J. surname: Mandrekar fullname: Mandrekar, Sumithra J. |
BookMark | eNp1UctOHDEQtBAR7zNXS1xyWfBjbM9cIm1WG0AC5bCEq-Xx9IAjrw32zErc-Ih8IV-Cl0VRQEpfutVdVaru3kfbIQZA6JiSU84bcmZNsJAyZZRyJugW2mNEsYmUTbX9T72LjnL-TUpwTpVUO2i3FKImNdlDi2m3KhqA5ysIA_4-pg4CXtiY4OX5zxTflqEZnAe8GJdLk57wNZg8JsB9THj25gDPvAvOGo9vkjM-H6IvfUlw9J4P0K8f85vZxeTq5_nlbHo1sZWshonsmqrmBpq2la1VgkkOPVcgut4YRU3TM1m6gkGrmhZqwlVdt7SRvGwlQPED9G2j-zC2S-hsWSAZrx-SWxvV0Tj9cRLcvb6LK63KVRitisDXd4EUH0fIg166bMF7EyCOWbNK1IqpSjUFerKB3hkP2oU-FkW7huuprARhXHJSUGcblE0x5wT9XzOU6PXP9KefFYb4xLBuKAePa8fO_5f3CvfOnag |
CitedBy_id | crossref_primary_10_1080_10543406_2025_2456176 crossref_primary_10_3389_fonc_2023_1211544 crossref_primary_10_1016_j_clinthera_2023_10_007 crossref_primary_10_1016_j_ijrobp_2021_11_024 crossref_primary_10_1080_19466315_2023_2166099 crossref_primary_10_1200_JCO_24_00979 crossref_primary_10_1186_s12874_021_01368_w crossref_primary_10_1111_rssc_12582 crossref_primary_10_3390_cancers17061039 crossref_primary_10_1016_S2352_3026_22_00045_X crossref_primary_10_1038_s41375_021_01342_x crossref_primary_10_1080_1120009X_2024_2302736 crossref_primary_10_1136_bmjopen_2021_053456 crossref_primary_10_3390_cancers15041344 crossref_primary_10_3390_jcm11206178 crossref_primary_10_1136_jitc_2022_005493 crossref_primary_10_1182_blood_2022018818 crossref_primary_10_1007_s00270_023_03391_4 crossref_primary_10_1016_S2352_3026_22_00226_5 crossref_primary_10_4049_jimmunol_2300185 crossref_primary_10_3390_cancers13112741 |
Cites_doi | 10.1198/016214504000000043 10.1111/rssc.12117 10.1016/j.ctrv.2019.04.004 10.1093/annonc/mdx043 10.2147/CMAR.S166468 10.1016/S2352-3026(20)30067-3 10.1016/S1470-2045(16)00038-3 10.1002/cncr.29544 10.1016/j.lungcan.2007.10.003 10.1200/JCO.2009.27.4282 10.1056/NEJMoa1805052 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2020 MDPI AG 2020 by the authors. 2020 |
Copyright_xml | – notice: COPYRIGHT 2020 MDPI AG – notice: 2020 by the authors. 2020 |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.3390/cancers12113251 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2072-6694 |
ExternalDocumentID | PMC7694214 A645023630 10_3390_cancers12113251 |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 7X8 PQGLB PUEGO 5PM |
ID | FETCH-LOGICAL-c464t-6d9483ae9bb6bc75263ef37e5dfaa71a9f2675252eb79be803788b19636695e73 |
IEDL.DBID | M48 |
ISSN | 2072-6694 |
IngestDate | Thu Aug 21 18:21:25 EDT 2025 Fri Sep 05 06:19:57 EDT 2025 Tue Jun 17 21:35:03 EDT 2025 Tue Jul 01 01:52:06 EDT 2025 Thu Apr 24 23:09:38 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c464t-6d9483ae9bb6bc75263ef37e5dfaa71a9f2675252eb79be803788b19636695e73 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-2234-7430 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers12113251 |
PMID | 33158080 |
PQID | 2458727479 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7694214 proquest_miscellaneous_2458727479 gale_infotracmisc_A645023630 crossref_primary_10_3390_cancers12113251 crossref_citationtrail_10_3390_cancers12113251 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20201104 |
PublicationDateYYYYMMDD | 2020-11-04 |
PublicationDate_xml | – month: 11 year: 2020 text: 20201104 day: 4 |
PublicationDecade | 2020 |
PublicationTitle | Cancers |
PublicationYear | 2020 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Gounder (ref_8) 2018; 379 George (ref_13) 2019; 76 Johnson (ref_7) 2008; 60 Schuurhuizen (ref_6) 2018; 10 Tseng (ref_4) 2015; 121 Bekele (ref_3) 2004; 99 Thanarajasingam (ref_10) 2020; 7 ref_1 Hobbs (ref_5) 2016; 65 Hillman (ref_11) 2010; 28 Hillman (ref_12) 2017; 28 ref_2 Thanarajasingam (ref_9) 2016; 17 |
References_xml | – volume: 99 start-page: 26 year: 2004 ident: ref_3 article-title: Dose-finding based on multiple toxicities in a soft tissue sarcoma trial publication-title: J. Am. Stat. Assoc. doi: 10.1198/016214504000000043 – volume: 65 start-page: 273 year: 2016 ident: ref_5 article-title: Bayesian group sequential clinical trial design using total toxicity burden and progression-free survival publication-title: J. R. Stat. Soc. Ser. C doi: 10.1111/rssc.12117 – ident: ref_2 – volume: 76 start-page: 33 year: 2019 ident: ref_13 article-title: Improving attribution of adverse events in oncology clinical trial publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2019.04.004 – volume: 28 start-page: 1183 year: 2017 ident: ref_12 article-title: Value of adverse events relatedness to study treatment: Analyses of data from randomized double-blind placebo-controlled clinical trials publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx043 – volume: 10 start-page: 3015 year: 2018 ident: ref_6 article-title: The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy publication-title: Cancer Manag. Res. doi: 10.2147/CMAR.S166468 – volume: 7 start-page: e490 year: 2020 ident: ref_10 article-title: Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: A case study of lenalidomide in the CALGB 50401 (Alliance) trial publication-title: Lancet Haematol. doi: 10.1016/S2352-3026(20)30067-3 – volume: 17 start-page: 663 year: 2016 ident: ref_9 article-title: Longitudinal adverse event assessment in oncology clinical trials: The Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)00038-3 – volume: 121 start-page: 3659 year: 2015 ident: ref_4 article-title: Phase I adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high risk extremity and trunk soft tissue sarcoma publication-title: Cancer doi: 10.1002/cncr.29544 – volume: 60 start-page: 200 year: 2008 ident: ref_7 article-title: Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51) publication-title: Lung Cancer doi: 10.1016/j.lungcan.2007.10.003 – ident: ref_1 – volume: 28 start-page: 3002 year: 2010 ident: ref_11 article-title: Evaluation of the Value of Attribution in the Interpretation of Adverse Event Data: A North Central Cancer Treatment Group and American College of Surgeons Oncology Group Investigation publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.27.4282 – volume: 379 start-page: 2417 year: 2018 ident: ref_8 article-title: Sorafenib for Advanced and Refractory Desmoid Tumors publication-title: N. Engl J. Med. doi: 10.1056/NEJMoa1805052 |
SSID | ssj0000331767 |
Score | 2.354484 |
Snippet | This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient... In cancer clinical trials, adverse event data are collected after every treatment cycle, using the Common Terminology Criteria for adverse events, which... |
SourceID | pubmedcentral proquest gale crossref |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 3251 |
SubjectTerms | Cancer Care and treatment Clinical trials Methods |
Title | Adverse Event Burden Score—A Versatile Summary Measure for Cancer Clinical Trials |
URI | https://www.proquest.com/docview/2458727479 https://pubmed.ncbi.nlm.nih.gov/PMC7694214 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB5RkBAXRGmrhke0SBx6MY336T0glKIAQgqqGiLlZnnXa1EpMiUJEtz4EfxCfgkztnlF9MJ5d21rHjvzrWe_AdjlQqHXuDzKvUSAIooiSqR1kbQYLPJOxoWvCmTP9MlQno7U6KUdUCPA6bvQjvpJDSfjvZur2wN0-H1CnAjZf3qSz2RKZGWC03XqJQxLnEy83-T61bYsMFRqU9P7vLduBZZxikoqishXQWp-q54vn3wVj47WYLVJJFm31vxnWAjlOiz3m1_lX2BQtVqeBtajikZWX1dgA2KtfLi77zI6KEOtjAMb1PfXWL8-LmSYxrLD6qNZwxo6ZueVnX6F4VHv_PAkajooRF5qOYt0bmUismCd084bxbUIhTBB5UWWmTizBUfAwBUPzlgXkg6xyztySq2tCkZ8g8XysgzfgcW6QHSmvSwyJ7XLrfcBkx-rCszJRJy3YO9JZKlv6MWpy8U4RZhB4k7nxN2CH88L_tXMGv-fukU6SMkK8JkePcCnXS0V0d-LTgt2nnST0hCVjZXh8nqacqkSQ7jbtsC8UdrzK4le--1I-feiotk22koey40Pr9yEFU7onA6h5RYszibXYRtTmJlrw9Kv3tnvP234dDyK25WhPgK4XvYk |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adverse+Event+Burden+Score%E2%80%94A+Versatile+Summary+Measure+for+Cancer+Clinical+Trials&rft.jtitle=Cancers&rft.au=Le-Rademacher%2C+Jennifer+G.&rft.au=Hillman%2C+Shauna&rft.au=Storrick%2C+Elizabeth&rft.au=Mahoney%2C+Michelle+R.&rft.date=2020-11-04&rft.pub=MDPI&rft.eissn=2072-6694&rft.volume=12&rft.issue=11&rft_id=info:doi/10.3390%2Fcancers12113251&rft_id=info%3Apmid%2F33158080&rft.externalDocID=PMC7694214 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |